A
ALX Oncology Holdings D
D
ALXO
1.11500
USD
-0.01
(-0.89%)
مغلق
حجم التداول
7,795
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
58,808,561
المقالات
العنوان: ALX Oncology Holdings
القطاع: Healthcare
الصناعة: Biotechnology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.